Zhejiang Tailin Bioengineering Co Ltd (300813) - Total Liabilities
Based on the latest financial reports, Zhejiang Tailin Bioengineering Co Ltd (300813) has total liabilities worth CN¥140.46 Million CNY (≈ $20.55 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Zhejiang Tailin Bioengineering Co Ltd - Total Liabilities Trend (2013–2025)
This chart illustrates how Zhejiang Tailin Bioengineering Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See 300813 working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Zhejiang Tailin Bioengineering Co Ltd Competitors by Total Liabilities
The table below lists competitors of Zhejiang Tailin Bioengineering Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Guizhou Wire Rope Co Ltd
SHG:600992
|
China | CN¥2.98 Billion |
|
Natures Sunshine Products Inc
NASDAQ:NATR
|
USA | $94.54 Million |
|
Shenzhen Jianyi Decoration Group Co Ltd
SHE:002789
|
China | CN¥9.81 Billion |
|
Zhejiang Busen Garments Co Ltd
SHE:002569
|
China | CN¥179.11 Million |
|
Power Wind Health Industry Incorporated
TW:8462
|
Taiwan | NT$9.35 Billion |
|
Australian Ethical Investment Ltd
AU:AEF
|
Australia | AU$23.66 Million |
|
Genie Energy Ltd
NYSE:GNE
|
USA | $131.15 Million |
|
Ausgold Ltd
AU:AUC
|
Australia | AU$23.51 Million |
Liability Composition Analysis (2013–2025)
This chart breaks down Zhejiang Tailin Bioengineering Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 300813 market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zhejiang Tailin Bioengineering Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zhejiang Tailin Bioengineering Co Ltd (2013–2025)
The table below shows the annual total liabilities of Zhejiang Tailin Bioengineering Co Ltd from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥155.04 Million ≈ $22.69 Million |
+11.40% |
| 2024-12-31 | CN¥139.18 Million ≈ $20.37 Million |
-56.95% |
| 2023-12-31 | CN¥323.27 Million ≈ $47.30 Million |
+17.46% |
| 2022-12-31 | CN¥275.21 Million ≈ $40.27 Million |
+73.64% |
| 2021-12-31 | CN¥158.49 Million ≈ $23.19 Million |
+65.53% |
| 2020-12-31 | CN¥95.75 Million ≈ $14.01 Million |
+153.27% |
| 2019-12-31 | CN¥37.81 Million ≈ $5.53 Million |
-37.43% |
| 2018-12-31 | CN¥60.42 Million ≈ $8.84 Million |
+28.27% |
| 2017-12-31 | CN¥47.10 Million ≈ $6.89 Million |
+18.77% |
| 2016-12-31 | CN¥39.66 Million ≈ $5.80 Million |
+17.37% |
| 2015-12-31 | CN¥33.79 Million ≈ $4.94 Million |
+44.71% |
| 2014-12-31 | CN¥23.35 Million ≈ $3.42 Million |
+36.89% |
| 2013-12-31 | CN¥17.06 Million ≈ $2.50 Million |
-- |
About Zhejiang Tailin Bioengineering Co Ltd
Zhejiang Tailin BioEngineering Co.,Ltd research and development, production, and sells microbial detection, contamination control, process analysis, and inhibition protection in the life sciences field in China and internationally. It primarily provides aseptic production and contamination control equipment, microbial testing products, and organic matter analysis technology products. The company … Read more